Progressive Supranuclear Palsy News and Research

RSS

Neuropathologist receives AAN Potamkin Prize for Alzheimer's disease research

Neuropathologist receives AAN Potamkin Prize for Alzheimer's disease research

The American Academy of Neurology has awarded the 2011 Potamkin Prize to Dennis Dickson, M.D., a neuropathologist at Mayo Clinic in Florida and the Robert E. Jacoby Professor for Alzheimer's Disease Research.

3 Mar 2011

Noscira receives FDA approval for Tideglusib drug to treat PSP

Noscira receives FDA approval for Tideglusib drug to treat PSP

Noscira, a Grupo Zeltia subsidiary specialized in research and development of drugs to treat neurodegenerative diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to its neuroprotector drug Tideglusib (ZentylorTM) to treat Progressive Supranuclear Palsy (PSP), a fast-advancing fatal degenerative brain disorder.

10 Sep 2010

Neurodegenerative disorders are the second-leading cause of early-onset dementia, says report

Neurodegenerative disorders are the second-leading cause of early-onset dementia, says report

Neurodegenerative disorders called frontotemporal dementias (FTD) are the second-leading cause of early-onset dementia in persons under age 65 and can emerge sometimes as early as age 20.

21 Sep 2009

Discovery of mechanism that may explain Parkinson's and other neurological disorders

Discovery of mechanism that may explain Parkinson's and other neurological disorders

Studying just eight families worldwide, the international team of researchers have discovered a genetic defect that results in profound depression and parkinsonism in a disorder known as Perry syndrome.

12 Jan 2009

Blood test for Parkinson's shows promise

Blood test for Parkinson's shows promise

A test that profiles molecular biomarkers in blood could become the first accurate diagnostic test for Parkinson's disease, new research shows.

12 Mar 2008

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.